Verona Pharma

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Verona Pharma and other ETFs, options, and stocks.

About VRNA

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

CEO

David S. Zaccardelli

CEODavid S. Zaccardelli

Employees

209

Employees209

Headquarters

London, Greater London

HeadquartersLondon, Greater London

Founded

2005

Founded2005

Employees

209

Employees209

VRNA Key Statistics

Market cap

8.92B

Market cap8.92B

Price-Earnings ratio

-51.44

Price-Earnings ratio-51.44

Dividend yield

—

Dividend yield—

Average volume

9.93M

Average volume9.93M

High today

$104.93

High today$104.93

Low today

$104.65

Low today$104.65

Open price

$104.85

Open price$104.85

Volume

10.92M

Volume10.92M

52 Week high

$104.99

52 Week high$104.99

52 Week low

$17.96

52 Week low$17.96

VRNA News

TipRanks 2d

Verona Pharma downgraded to Hold from Buy at Truist

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100, following Merck’s (MRK) $10B proposal to acquire all Verona f...

Seeking Alpha 3d

Merck confirms $10B buyout of Verona Pharma

Update: Adds deal confirmation Merck (NYSE:MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma (NASDAQ:VRNA), a biotech firm specializi...

TipRanks 3d

Merck to acquire Verona Pharma for $107.00 per ADS

06:31 EDT Merck (MRK) to acquire Verona Pharma (VRNA) for $107.00 per ADS Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Analyst ratings

83%

of 12 ratings

Buy

16.7%

Hold

83.3%

Sell